Health  Vol.7 No.9 , September 2015
Cardiovascular Benefits of Testosterone Replacement Therapy in the Andropausal Male
Abstract: Androgen deficiency has been receiving a lot of attention as an evolving health concern in the in-dustrialized world. With population aging, hypogonadism has become a challenging medical problem confronting practicing physicians. The importance of this increasingly prevalent disease arises from its potentially debilitating and serious consequences, such as atherosclerosis, diabetes mellitus, metabolic disorders, muscular weakness, psychiatric illness, sexual dysfunction and vascular inflammation. When left untreated, testosterone deficiency is associated with increased cardiovascular mortality.
Cite this paper: Vatti, S. , Madanieh, R. , Madanieh, A. , Kosmas, C. and Vittorio, T. (2015) Cardiovascular Benefits of Testosterone Replacement Therapy in the Andropausal Male. Health, 7, 1206-1214. doi: 10.4236/health.2015.79135.

[1]   Basaria, S. (2013) Reproductive Aging in Men. Endocrinology and Metabolism Clinics of North America, 42, 255-270.

[2]   La Torre, D. and Falorni, A. (2007) Pharmacological Causes of Hyperprolactinemia. Therapeutics and Clinical Risk Management, 3, 929-951.

[3]   Dana, O. and Susanne, Q. (2006) Clinical Hypogonadism and Androgen Replacement Therapy: An Overview. Urologic Nursing, 226, 253-259.

[4]   Ullah, M.I., Riche, D.M. and Koch, C.A. (2014) Transdermal Testosterone Replacement Therapy in Men. Drug Design, Development and Therapy, 8, 101-112.

[5]   Huhtaniemi, I. (2014) Late-Onset Hypogonadism: Current Concepts and Controversies of Pathogenesis, Diagnosis and Treatment. Asian Journal of Andrology, 6, 192-202.

[6]   Jeng, H.A. (2014) Exposure to Endocrine Disrupting Chemicals and Male Reproductive Health. Frontiers in Public Health, 22, 1-4.

[7]   Surampudi, P., Swerdloff, R.S. and Wang, C. (2014) An Update on Male Hypogonadism Therapy. Expert Opinion Pharmacotherapy, 15, 1247-1264.

[8]   Bhasin, S., Cunningham, G.R., Hayes, F.J., Matsumoto, A.M., et al. (2010) Testosterone Therapy in Men with Androgen Deficiency Syndromes: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology and Metabolism, 95, 2536-2559.

[9]   Grober, E.D. (2014) Testosterone Deficiency and Replacement: Myths and Realities. Canadian Urological Association Journal, 8, s145-s147.

[10]   Miner, M., Barkin, J. and Rosenberg, M.T. (2014) Testosterone Deficiency: Myths Facts and Controversy. Canadian Journal of Urology, Suppl. 2, 39-54.

[11]   Handelsman, D.J. and Zajac, J.D. (2004) Androgen Deficiency and Replacement Therapy in Men. Medical Journal of Australia, 180, 529-535.

[12]   Chik, Z., Johnston, A., Tucker, A.T., Chew, S.L., et al. (2005) Pharmacokinetics of a New Testosterone Transdermal Delivery System, TDS-Testosterone in Healthy Males. British Journal of Clinical Pharmacology, 61, 275-279.

[13]   Salehian, B., Wang, C., Alexander, G., Davidson, T., et al. (1995) Pharmacokinetics, Bioefficacy, and Safety of Sublingual Testosterone Cyclodextrin in Hypogonadal Men: Comparison to Testosterone Enanthate—A Clinical Research Center Study. Journal of Clinical Endocrinology and Metabolism, 80, 3567-3575.

[14]   Hellstrom, W.J.G. (2004) Testosterone Replacement Therapy. Scientific World Journal, 4, 142-149.

[15]   Holmegard, H.N., Nordestgaard, B.G., Schnohr, P., Tybjaerg-Hansen, A. and Benn, M. (2014) Endogenous Sex Hormones and Risk of Venous Thromboembolism in Women and Men. Journal of Thrombosis and Haemostasis, 12, 297-305.

[16]   Baillargeon, J., Urban, R.J., Kuo, Y.F., Ottenbacher, K.J., et al. (2014) Risk of Myocardial Infarction in Older Men Receiving Testosterone Therapy. Annals of Pharmacotherapy, 48, 1138-1144.

[17]   Finkle, W.D., Greenland, S., Ridgeway, G.K., Adams, J.L., Frasco, M.A., et al. (2014) Increased Risk of Non-Fatal Myocardial Infarction Following Testosterone Therapy Prescription in Men. PLoS ONE, 9, e85805.

[18]   Vigen, R., O’Donnell, C.I., Baron, A.E., Grunwald, G.K., Maddox, T.M., et al. (2013) Association of Testosterone Therapy with Mortality, Myocardial Infarction, and Stroke in Men With Low Testosterone Levels. Journal of the American Medical Association, 310, 1829-1836.

[19]   Malkin, C.J., Pugh, P.J., Morris, P.D., Kerry, K.E., Jones, R.D., Jones, T.H. and Channer, K.S. (2004) Testosterone Replacement in Hypogonadal Men with Angina Improves Ischemic Threshold and Quality of Life. Heart Journal, 90, 871-876.

[20]   Mathur, A., Malkin, C., Saeed, B., Muthusamy, R., Jones, T.H. and Channer, K. (2009) Long-Term Benefits of Testosterone Replacement Therapy on Angina Threshold and Atheroma in Men. European Journal of Endocrinology, 161, 443-449.

[21]   Yaron, M., Greenman, Y., Rosenfeld, J., Izkhakov, E., Limor, R., et al. (2009) Effect of Testosterone Replacement Therapy on Arterial Stiffness in Older Hypogonadal Men. European Journal of Endocrinology, 160, 839-846.

[22]   Edward, W., Dennis, V., Ali, E., Luigi, F. and John, H. (2012) Dehydroepiandrosterone Replacement Therapy in Older Adults Improves Indices of Arterial Stiffness. Aging Cell Journal, 11, 876-884.

[23]   Nichols, W.W. and Singh, B.M. (2002) Augmentation Index as a Measure of Peripheral Vascular Disease State. Current Opinion in Cardiology, 17, 543-551.

[24]   Poongothai, S., Pradeepa, R., Indulekha, K., Surendar, J., et al. (2015) Association of Depression with Common Carotid Artery Intima Media Thickness and Augmentation Index in a Large Urban South Indian Population—The Chennai Urban Rural Epidemiology Study (CURES-138). Indian Journal of Endocrinology and Metabolism, 19, 136-142.

[25]   Farias, J.M., Tinetti, M., Khoury, M. and Umpierrez, G.E. (2014) Low Testosterone Concentration and Atherosclerotic Disease Markers in Male Patients with Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 99, 4698-4703.

[26]   Kalinchenko, S.Y., Tishova, Y.A., Mskhalaya, G.J., Gooren, L.J.G., et al. (2010) Effects of Testosterone Supplementation on Markers of the Metabolic Syndrome and Inflammation in Hypogonadal Men with the Metabolic Syndrome: The Double-Blinded Placebo-Controlled Moscow Study. Clinical Endocrinology, 73, 602-612.

[27]   He, J., Bhasin, S., Binder, E.F., Yarasheski, K.E., et al. (2013) Cardio Metabolic Risks during Anabolic Hormone Supplementation in Older Men. Obesity Journal, 21, 968-975.

[28]   Saad, F., Haider, A., Doros, G. and Traish, A. (2013) Long Term Treatment of Hypogonadal Men with Testosterone Produces Substantial and Sustained Weight Loss. Obesity, 21, 1975-1981.

[29]   Frederiksen, L., Hojlund, K., Hougaard, D.M., Brixen, K. and Andersen, M. (2012) Testosterone Therapy Increased Muscle Mass and Lipid Oxidation in Aging Men. AGE, 34, 145-156.

[30]   Snyder, P.J., Peachey, H., Hannoush, P., Berlin, J.A., Loh, L., et al. (1999) Effect of Testosterone Treatment on Body Composition and Muscle Strength in Men over 65 Years of Age. Journal of Clinical Endocrinology and Metabolism, 84, 2647-2653.

[31]   Ferrando, A.A., Sheffield-Moore, M., Yeckel, C.W., Gilkison, C., Jiang, J., et al. (2002) Testosterone Administration to Older Men Improves Muscle Function: Molecular and Physiological Mechanisms. American Journal of Physiology, Endocrinology and Metabolism, 282, E601-E607.